van Oterendorp, Christian

[["dc.bibliographiccitation.firstpage","397"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Investigative Ophthalmology & Visual Science"],["dc.bibliographiccitation.lastpage","406"],["dc.bibliographiccitation.volume","60"],["dc.contributor.author","Gottschalk, Hanna M."],["dc.contributor.author","Wecker, Thomas"],["dc.contributor.author","Khattab, Mohammed H."],["dc.contributor.author","Fischer, Charlotte V."],["dc.contributor.author","Callizo, Josep"],["dc.contributor.author","Rehfeldt, Florian"],["dc.contributor.author","Lubjuhn, Roswitha"],["dc.contributor.author","Russmann, Christoph"],["dc.contributor.author","Hoerauf, Hans"],["dc.contributor.author","van Oterendorp, Christian"],["dc.date.accessioned","2019-07-09T11:50:10Z"],["dc.date.available","2019-07-09T11:50:10Z"],["dc.date.issued","2019"],["dc.description.abstract","Purpose: Contrast agents applicable for optical coherence tomography (OCT) imaging are rare. The intrascleral aqueous drainage system would be a potential application for a contrast agent, because the aqueous veins are of small diameter and located deep inside the highly scattering sclera. We tested lipid emulsions (LEs) as candidate OCT contrast agents in vitro and ex vivo, including milk and the anesthetic substance Propofol. Methods: Commercial OCT and OCT angiography (OCTA) devices were used. Maximum reflectivity and signal transmission of LE were determined in tube phantoms. Absorption spectra and light scattering was analyzed. The anterior chamber of enucleated porcine eyes was perfused with LEs, and OCTA imaging of the LEs drained via the aqueous outflow tract was performed. Results: All LEs showed a significantly higher reflectivity than water (P < 0.001). Higher milk lipid content was positively correlated with maximum reflectivity and negatively with signal transmission. Propofol exhibited the best overall performance. Due to a high degree of signal fluctuation, OCTA could be applied for detection of LE. Compared with blood, the OCTA signal of Propofol was significantly stronger (P = 0.001). As a proof of concept, time-resolved aqueous angiography of porcine eyes was performed. The three-dimensional (3D) structure and dynamics of the aqueous outflow were significantly different from humans. Conclusions: LEs induced a strong signal in OCT and OCTA. LE-based OCTA allowed the ability to obtain time-resolved 3D datasets of aqueous outflow. Possible interactions of LE with inner eye's structures need to be further investigated before in vivo application."],["dc.identifier.doi","10.1167/iovs.18-25223"],["dc.identifier.pmid","30682210"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15874"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59715"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1552-5783"],["dc.rights","CC BY-NC-ND 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc-nd/4.0"],["dc.subject.ddc","610"],["dc.title","Lipid Emulsion-Based OCT Angiography for Ex Vivo Imaging of the Aqueous Outflow Tract."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","100031"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Ophthalmology Science"],["dc.bibliographiccitation.volume","1"],["dc.contributor.author","Bemme, Sebastian"],["dc.contributor.author","Heins, Amelie"],["dc.contributor.author","Lauermann, Peer"],["dc.contributor.author","Storch, Marcus Werner"],["dc.contributor.author","Khattab, Mohammed Haitham"],["dc.contributor.author","Hoerauf, Hans"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","van Oterendorp, Christian"],["dc.date.accessioned","2022-05-13T06:27:45Z"],["dc.date.available","2022-05-13T06:27:45Z"],["dc.date.issued","2021"],["dc.description.sponsorship","Open-Access-Publikationsfonds 2021"],["dc.identifier.doi","10.1016/j.xops.2021.100031"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/107850"],["dc.language.iso","en"],["dc.relation.issn","2666-9145"],["dc.rights","CC BY-NC-ND 4.0"],["dc.title","Reliability of Subjective Assessment of Spectral-Domain OCT Pathologic Features by Multiple Raters in Retinal Vein Occlusion"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2753"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","Graefe s Archive for Clinical and Experimental Ophthalmology"],["dc.bibliographiccitation.lastpage","2760"],["dc.bibliographiccitation.volume","251"],["dc.contributor.author","Jordan, Jens F."],["dc.contributor.author","Wecker, Thomas"],["dc.contributor.author","van Oterendorp, Christian"],["dc.contributor.author","Anton, Alexandra"],["dc.contributor.author","Reinhard, Thomas"],["dc.contributor.author","Boehringer, Daniel"],["dc.contributor.author","Neuburger, Matthias"],["dc.date.accessioned","2018-11-07T09:17:02Z"],["dc.date.available","2018-11-07T09:17:02Z"],["dc.date.issued","2013"],["dc.description.abstract","In most forms of open angle glaucoma, the trabecular meshwork is the main barrier for aqueous humor outflow, causing elevated intraocular pressure (IOP). The Trabectome is a minimal invasive device for the surgical treatment of open angle glaucoma, particularly eliminating the juxtacanalicular meshwork. This study was conducted to compare the effectiveness and complication profile among different glaucoma subgroups. Single center prospective observational study. There were 557 consecutive eyes of 487 patients included in this study. Trabectome surgery was performed either alone or in combination with cataract surgery. Intraoperative and postoperative complications were documented systematically. Main outcome measures were IOP reduction over time and the preoperative and postoperative number of IOP-lowering medications. Due to subgroup sizes, only data from eyes with primary open angle glaucoma and pseudoexfoliation glaucoma were processed for statistical analysis. For the 261 eyes classified as primary open angle glaucoma, preoperative IOP was 24 +/- 5.5 mmHg (mean +/- SD) under 2.1 +/- 1.3 IOP-lowering medications. After a mean follow-up of 204 +/- 238 days, IOP was reduced to 18 +/- 6.1 mmHg, and medication was reduced to 1.2 +/- 1.1. For the 173 eyes classified as pseudoexfoliation glaucoma, after a mean follow-up of 200 +/- 278 days, IOP was reduced from 25 +/- 5.9 mmHg to 18 +/- 8.2 mmHg, and medication was reduced from 2.0 +/- 1.2 to 1.1 +/- 1.1. A Cox proportional hazards model hinted forward superiority of the combined surgery cases (Trabectome + Phaco + intraocular lens) in comparison to Trabectome surgery only in phakic or pseudophakic eyes. No serious complications were observed. Minimal invasive glaucoma surgery with the Trabectome seems to be safe and effective. The subgroup analysis of different kinds of open angle glaucomas presented in this study may help in first-line patient selection. The lack of ocular surface alterations makes it a valuable addition to glaucoma surgery."],["dc.identifier.doi","10.1007/s00417-013-2500-7"],["dc.identifier.isi","000328345000012"],["dc.identifier.pmid","24158374"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/10945"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/28070"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","1435-702X"],["dc.relation.issn","0721-832X"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Trabectome surgery for primary and secondary open angle glaucomas"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e010956"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","BMJ Open"],["dc.bibliographiccitation.volume","6"],["dc.contributor.author","Diem, Ricarda"],["dc.contributor.author","Molnar, Fanni"],["dc.contributor.author","Beisse, Flemming"],["dc.contributor.author","Gross, Nikolai"],["dc.contributor.author","Drueschler, Katharina"],["dc.contributor.author","Heinrich, Sven P."],["dc.contributor.author","Joachimsen, Lutz"],["dc.contributor.author","Rauer, Sebastian"],["dc.contributor.author","Pielen, Amelie"],["dc.contributor.author","Suehs, Kurt-Wolfram"],["dc.contributor.author","Linker, Ralf Andreas"],["dc.contributor.author","Huchzermeyer, Cord"],["dc.contributor.author","Albrecht, Philipp"],["dc.contributor.author","Hassenstein, Andrea"],["dc.contributor.author","Aktas, Orhan"],["dc.contributor.author","Guthoff, Tanja"],["dc.contributor.author","Tonagel, Felix"],["dc.contributor.author","Kernstock, Christoph"],["dc.contributor.author","Hartmann, Kathrin"],["dc.contributor.author","Kuempfel, Tania"],["dc.contributor.author","Hein, Katharina"],["dc.contributor.author","van Oterendorp, Christian"],["dc.contributor.author","Grotejohann, Birgit"],["dc.contributor.author","Ihorst, Gabriele"],["dc.contributor.author","Maurer, Julia"],["dc.contributor.author","Mueller, Matthias"],["dc.contributor.author","Volkmann, Martin"],["dc.contributor.author","Wildemann, Brigitte"],["dc.contributor.author","Platten, Michael"],["dc.contributor.author","Wick, Wolfgang"],["dc.contributor.author","Heesen, Christoph"],["dc.contributor.author","Schiefer, Ulrich"],["dc.contributor.author","Wolf, Sebastian"],["dc.contributor.author","Lagreze, Wolf A."],["dc.date.accessioned","2018-11-07T10:20:35Z"],["dc.date.available","2018-11-07T10:20:35Z"],["dc.date.issued","2016"],["dc.description.abstract","Introduction Optic neuritis leads to degeneration of retinal ganglion cells whose axons form the optic nerve. The standard treatment is a methylprednisolone pulse therapy. This treatment slightly shortens the time of recovery but does not prevent neurodegeneration and persistent visual impairment. In a phase II trial performed in preparation of this study, we have shown that erythropoietin protects global retinal nerve fibre layer thickness (RNFLT-G) in acute optic neuritis; however, the preparatory trial was not powered to show effects on visual function. Methods and analysis Treatment of Optic Neuritis with Erythropoietin (TONE) is a national, randomised, double-blind, placebo-controlled, multicentre trial with two parallel arms. The primary objective is to determine the efficacy of erythropoietin compared to placebo given add-on to methylprednisolone as assessed by measurements of RNFLT-G and low-contrast visual acuity in the affected eye 6months after randomisation. Inclusion criteria are a first episode of optic neuritis with decreased visual acuity to 0.5 (decimal system) and an onset of symptoms within 10days prior to inclusion. The most important exclusion criteria are history of optic neuritis or multiple sclerosis or any ocular disease (affected or non-affected eye), significant hyperopia, myopia or astigmatism, elevated blood pressure, thrombotic events or malignancy. After randomisation, patients either receive 33000 international units human recombinant erythropoietin intravenously for 3 consecutive days or placebo (0.9% saline) administered intravenously. With an estimated power of 80%, the calculated sample size is 100 patients. The trial started in September 2014 with a planned recruitment period of 30months. Ethics and dissemination TONE has been approved by the Central Ethics Commission in Freiburg (194/14) and the German Federal Institute for Drugs and Medical Devices (61-3910-4039831). It complies with the Declaration of Helsinki, local laws and ICH-GCP. Trial registration number NCT01962571."],["dc.identifier.doi","10.1136/bmjopen-2015-010956"],["dc.identifier.isi","000374052300146"],["dc.identifier.pmid","26932144"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/13259"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41917"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Bmj Publishing Group"],["dc.relation.issn","2044-6055"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0"],["dc.title","Treatment of optic neuritis with erythropoietin (TONE): a randomised, double-blind, placebo-controlled trialstudy protocol"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","e0241005"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","PLoS One"],["dc.bibliographiccitation.volume","15"],["dc.contributor.author","Lauermann, Peer"],["dc.contributor.author","Gebest, Julia"],["dc.contributor.author","Pfeiffer, Sebastian"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Bemme, Sebastian"],["dc.contributor.author","Hoerauf, Hans"],["dc.contributor.author","van Oterendorp, Christian"],["dc.contributor.editor","Grzybowski, Andrzej"],["dc.date.accessioned","2021-04-14T08:31:16Z"],["dc.date.available","2021-04-14T08:31:16Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1371/journal.pone.0241005"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17683"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/83535"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.notes.intern","Merged from goescholar"],["dc.relation.eissn","1932-6203"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Influence of pars plana vitrectomy for macular surgery on the medium term intraocular pressure"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","4970"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Investigative Opthalmology & Visual Science"],["dc.bibliographiccitation.volume","57"],["dc.contributor.author","Fischer, Charlotte V."],["dc.contributor.author","Mans, Viktoria"],["dc.contributor.author","Horn, Maren"],["dc.contributor.author","Naxer, Sabine"],["dc.contributor.author","Klettner, Alexa"],["dc.contributor.author","van Oterendorp, Christian"],["dc.date.accessioned","2019-07-09T11:43:03Z"],["dc.date.available","2019-07-09T11:43:03Z"],["dc.date.issued","2016"],["dc.description.abstract","PURPOSE. Vascular endothelial growth factor–signaling in human tenon fibroblasts (hTFs) has recently become a target for antifibrotic treatment in glaucoma filtration surgery. The anti- VEGF antibody bevacizumab (BVC) has been shown to increase filtration bleb size. Given the relatively high concentration of BVC needed to obtain an effect, we investigated whether BVC acts through VEGF inhibition or via non–antigen-dependent ways. METHODS. Human tenon fibroblast primary cultures were obtained from strabismus surgery subjects. Under low (0.2%) and high (10%) serum conditions, cells were incubated with BVC, ranibizumab (RNB), aflibercept (AFB), or rituximab (RTX) at different concentrations. Total number of cells and number of dead or proliferating (5-bromo-2-deoxy-uridinepositive) cells were assessed after 24 hours. Concentrations of VEGF-A in cell culture media was measured with ELISA. Intracellular IgG was detected with immunostaining and Western blot analysis. RESULTS. In quiescent hTF culture (0.2% serum) the addition of 5 mg/mL BVC induced widespread cell death. Under proliferative conditions (10% serum), BVC reduced the number of proliferating cells. No such effect was observed with 2.5 mg/mL BVC or with 10 mg/mL AFB or 2.5 mg/mL RNB, although they were equally effective in binding free VEGF-A in the culture media. Instead, the CD20 antibody RTX, which did not bind VEGF, induced hTF death and inhibited proliferation in a BVC-comparable fashion. Bevacizumab, AFB, and RTX were detected intracellularly in a concentration-dependent manner. CONCLUSIONS. The cell death–inducing and antiproliferative effect of 5 mg/mL BVC appeared not to depend on VEGF inhibition. Our data question a direct role of VEGF for hTF survival and proliferation."],["dc.identifier.doi","10.1167/iovs.16-19938"],["dc.identifier.pmid","27654424"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/14091"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58812"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1552-5783"],["dc.rights","CC BY-NC-ND 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc-nd/4.0"],["dc.title","The Antiproliferative Effect of Bevacizumab on Human Tenon Fibroblasts Is Not Mediated by Vascular Endothelial Growth Factor Inhibition"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1245"],["dc.bibliographiccitation.journal","Clinical Ophthalmology"],["dc.bibliographiccitation.lastpage","1254"],["dc.bibliographiccitation.volume","Volume 16"],["dc.contributor.author","Lauermann, Peer"],["dc.contributor.author","Klingelhöfer, Anthea"],["dc.contributor.author","Mielke, Dorothee"],["dc.contributor.author","Bahlmann, Dirk"],["dc.contributor.author","Hoerauf, Hans"],["dc.contributor.author","Koscielny, Juergen"],["dc.contributor.author","Sucker, Christoph"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","van Oterendorp, Christian"],["dc.date.accessioned","2022-06-01T09:39:46Z"],["dc.date.available","2022-06-01T09:39:46Z"],["dc.date.issued","2022"],["dc.description.abstract","Purpose: To evaluate the influences and risk factors for severe bleeding complications during glaucoma surgery, and to investigate the\r\nrole of antiplatelet (AP) and anticoagulant (AC) agents.\r\nMethods: This prospective study enrolled patients undergoing trabeculectomy, trabeculotomy (with Trabectome® or Kahook Dual\r\nBlade®), viscocanaloplasty and Ahmed or Baerveldt implants. Bleeding severity was graded on an ordinal scale ranging from 0 to 5.\r\nImmediately after surgery and one day later, the incidence and severity of bleeding events was documented on a standardized form. A grade\r\n≥3 was defined as severe bleeding. The influence of known systemic disorders, the type of anesthesia, surgical procedure, intraoperative\r\nblood pressure, and the use of or change in AP or AC agents on intraoperative bleeding were analyzed.\r\nResults: Data from 89 eyes undergoing glaucoma procedures were included (age 71.3y ± 10.5). We observed severe intraoperative\r\nbleeding in 8 eyes (9%) and found that concomitant diseases such as the history of a deep vein thrombosis or peripheral arterial\r\nocclusive disease, and the type of surgical procedure (trabeculectomy and viscocanaloplasty) were significantly associated with severe\r\nbleeding events. By contrast, the use of AP/ AC agents had no significant influence on severe intraoperative bleeding events.\r\nConclusion: According to the results of our study cohort, glaucoma procedures entailing scleral manipulations (trabeculectomy and\r\nviscocanaloplasty) and concomitant diseases such as the history of a deep vein thrombosis or peripheral arterial occlusive disease\r\ninfluence the risk of severe intraoperative bleeding events, we detected no increased risk related to concomitant antiplatelet and/ or\r\nanticoagulant medication use."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2022"],["dc.identifier.doi","10.2147/OPTH.S361867"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/108560"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-572"],["dc.relation.eissn","1177-5483"],["dc.rights","CC BY-NC 3.0"],["dc.title","Risk Factors for Severe Bleeding Complications in Glaucoma Surgery and the Role of Antiplatelet or Anticoagulant Agents"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","28"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Translational Vision Science & Technology"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Lauermann, Peer"],["dc.contributor.author","van Oterendorp, Christian"],["dc.contributor.author","Storch, Marcus W."],["dc.contributor.author","Khattab, Mohammed H."],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Hoerauf, Hans"],["dc.contributor.author","Bemme, Sebastian"],["dc.date.accessioned","2020-12-10T18:38:18Z"],["dc.date.available","2020-12-10T18:38:18Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1167/tvst.8.4.28"],["dc.identifier.issn","2164-2591"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16505"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77264"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY-NC-ND 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc-nd/4.0"],["dc.title","Distance-Thresholded Intercapillary Area Analysis Versus Vessel-Based Approaches to Quantify Retinal Ischemia in OCTA"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1643"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Graefe's Archive for Clinical and Experimental Ophthalmology"],["dc.bibliographiccitation.lastpage","1650"],["dc.bibliographiccitation.volume","255"],["dc.contributor.author","Wecker, Thomas"],["dc.contributor.author","Anton, Alexandra"],["dc.contributor.author","Neuburger, Matthias"],["dc.contributor.author","Jordan, Jens F."],["dc.contributor.author","van Oterendorp, Christian"],["dc.date.accessioned","2019-07-09T11:44:21Z"],["dc.date.available","2019-07-09T11:44:21Z"],["dc.date.issued","2017"],["dc.description.abstract","BACKGROUND: Trabeculotomy with the Trabectome® is an effective surgical procedure to lower intraocular pressure (IOP). However, in some patients it does not lead to a significant IOP reduction despite a gonioscopically well visible opening of Schlemm's canal. This study investigated whether the size of the trabeculotomy opening and other parameters, including anterior chamber depth (ACD) are related to IOP reduction. METHODS: Retrospective observational case series with 93 eyes of 93 patients who underwent Trabectome surgery. Trabeculotomy opening and ACD were measured with an anterior segment swept source OCT. IOP was taken pre-operatively and at a single follow-up visit [follow-up time 125 ± 66 days (mean ± SD)]. The relationship between IOP reduction and OCT parameters and possible confounding factors was analyzed in a multiple linear regression model. RESULTS: The trabeculotomy opening size did not correlate with IOP reduction (slope of regression line = 0.0016; 95% confidence interval of slope: -0.025 to 0.028). The same applied for all other parameters tested, including ACD, which showed a tendency towards better IOP reduction with a deeper AC (slope = -1.9; 95% confidence interval: -5.54 to 1.73). Comparison between the 1st and 4th quartile of the trabeculotomy opening showed a significantly higher ACD in the largest trabeculotomy opening quartile (3.32 ± 0.05 mm vs. 3.16 ± 0.04 mm; p = 0.031). CONCLUSIONS: The fact that the trabeculotomy opening size did not correlate with IOP reduction points to the poorly understood role of the intrascleral aqueous outflow pathway in glaucomatous IOP elevation. A deeper AC might be a factor promoting a larger trabeculotomy opening."],["dc.format.extent","8"],["dc.identifier.doi","10.1007/s00417-017-3683-0"],["dc.identifier.pmid","28528378"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/14725"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58996"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Trabeculotomy opening size and IOP reduction after Trabectome® surgery"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]